Pages that link to "Q35048054"
Jump to navigation
Jump to search
The following pages link to Augmenting antitumor immune responses with epigenetic modifying agents (Q35048054):
Displaying 50 items.
- Immune Mechanisms in Myelodysplastic Syndrome (Q26744500) (← links)
- Epigenetic control of HIV-1 post integration latency: implications for therapy (Q26781191) (← links)
- Targeting Epigenetic Processes in Photodynamic Therapy-Induced Anticancer Immunity (Q26797280) (← links)
- Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy (Q28066199) (← links)
- The Impact of Chemotherapy, Radiation and Epigenetic Modifiers in Cancer Cell Expression of Immune Inhibitory and Stimulatory Molecules and Anti-Tumor Efficacy (Q28076473) (← links)
- 3D Microfluidic model for evaluating immunotherapy efficacy by tracking dendritic cell behaviour toward tumor cells (Q30850591) (← links)
- DNA demethylating agent decitabine broadens the peripheral T cell receptor repertoire (Q37437334) (← links)
- Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma (Q37589140) (← links)
- Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical review (Q37724905) (← links)
- Human Leukocyte Antigen (HLA) Peptides Derived from Tumor Antigens Induced by Inhibition of DNA Methylation for Development of Drug-facilitated Immunotherapy. (Q38390185) (← links)
- Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock? (Q38664735) (← links)
- Marked for death: targeting epigenetic changes in cancer (Q38747872) (← links)
- Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy (Q38749824) (← links)
- Combining Epigenetic and Immunotherapy to Combat Cancer (Q38779204) (← links)
- Targeting the cancer epigenome for therapy (Q38821103) (← links)
- Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors (Q38838643) (← links)
- DNA Hypomethylating Drugs in Cancer Therapy (Q38979940) (← links)
- Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy (Q39130451) (← links)
- Digital analysis and epigenetic regulation of the signature of rejection in colorectal cancer. (Q40469741) (← links)
- Hallmarks of response to immune checkpoint blockade (Q41078811) (← links)
- DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer (Q41247038) (← links)
- Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment (Q41573313) (← links)
- Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors (Q41945124) (← links)
- Editorial: Advances in Combination Tumor Immunotherapy (Q42047687) (← links)
- Histone deacetylase inhibitors as cancer therapeutics (Q42106883) (← links)
- New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone (Q46047154) (← links)
- Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade (Q47135020) (← links)
- Decitabine enhances targeting of AML cells by CD34+ progenitor-derived NK cells in NOD/SCID/IL2Rgnull mice (Q47595821) (← links)
- Mechanisms of resistance to immune checkpoint inhibitors (Q49537326) (← links)
- Strategy to targeting the immune resistance and novel therapy in colorectal cancer. (Q52320729) (← links)
- Dying to Be Noticed: Epigenetic Regulation of Immunogenic Cell Death for Cancer Immunotherapy. (Q52581847) (← links)
- Decitabine Inhibits Gamma Delta T Cell Cytotoxicity by Promoting KIR2DL2/3 Expression. (Q52597632) (← links)
- Epigenetic Therapeutics and Their Impact in Immunotherapy of Lung Cancer. (Q52674783) (← links)
- Mechanisms of Resistance to PD-1 and PD-L1 Blockade. (Q52707883) (← links)
- Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. (Q53706033) (← links)
- The safety, efficacy, and treatment outcomes of a combination of low-dose decitabine treatment in patients with recurrent ovarian cancer. (Q53724500) (← links)
- Immune checkpoint therapy in liver cancer. (Q55008806) (← links)
- Immunotherapy With Human Gamma Delta T Cells-Synergistic Potential of Epigenetic Drugs? (Q55030400) (← links)
- Successful treatment of high-risk myelodysplastic syndrome with decitabine-based chemotherapy followed by haploidentical lymphocyte infusion: A case report and literature review. (Q55080752) (← links)
- Targeting the Immune Microenvironment in Acute Myeloid Leukemia: A Focus on T Cell Immunity. (Q55299267) (← links)
- Epigenetic mechanisms of tumor resistance to immunotherapy (Q56889801) (← links)
- DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer (Q56890318) (← links)
- The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer (Q57066369) (← links)
- Epigenetic treatment of multiple myeloma mediates tumor intrinsic and extrinsic immunomodulatory effects (Q57138927) (← links)
- (Q57806035) (← links)
- (Q57806045) (← links)
- Epigenetic therapy combinations in acute myeloid leukemia: what are the options? (Q61797217) (← links)
- Systemic Immunotherapy Effective for Refractory Extramedullary Acute Myeloid Leukemia (Q64297779) (← links)
- 5-Azacytidine inhaled dry powder formulation profoundly improves pharmacokinetics and efficacy for lung cancer therapy through genome reprogramming (Q89900894) (← links)
- Cancer Stem Cells: Devil or Savior-Looking behind the Scenes of Immunotherapy Failure (Q89975349) (← links)